Efficacy of a new ready-to-use vaccine against PCV-2d and Mycoplasma hyopneumoniae under experimental conditions

R Krejci, P Trampus, A Csagola, T Szalai, N Palmai, A Toth, N Terenyi, Z Nagy, Szeplaki Na, G Somogyi, T Barna, E Rausch, Z Penzes, M Szaszko and Z Lorincz
Additional contact information
R Krejci: Ceva Sante Animale, Libourne Cedex, France
P Trampus: Ceva-Phylaxia Zrt., Budapest, Hungary
A Csagola: Ceva-Phylaxia Zrt., Budapest, Hungary
T Szalai: Ceva-Phylaxia Zrt., Budapest, Hungary
N Palmai: Ceva-Phylaxia Zrt., Budapest, Hungary
A Toth: Ceva-Phylaxia Zrt., Budapest, Hungary
N Terenyi: Ceva-Phylaxia Zrt., Budapest, Hungary
Z Nagy: Ceva-Phylaxia Zrt., Budapest, Hungary
Szeplaki Na: Ceva-Phylaxia Zrt., Budapest, Hungary
G Somogyi: Ceva-Phylaxia Zrt., Budapest, Hungary
T Barna: Ceva-Phylaxia Zrt., Budapest, Hungary
E Rausch: Ceva-Phylaxia Zrt., Budapest, Hungary
Z Penzes: Ceva-Phylaxia Zrt., Budapest, Hungary
M Szaszko: TargetEx Biosciences Ltd., Dunakeszi, Hungary
Z Lorincz: TargetEx Biosciences Ltd., Dunakeszi, Hungary

Veterinární medicína, 2025, vol. 70, issue 6, 196-202

Abstract: Mycoplasma hyopneumoniae (M. hyo) and porcine circovirus type 2 (PCV-2) are major and widespread swine pathogens, both implicated in the porcine respiratory disease complex, which can lead to significant economic losses for pig producers. PCV-2d is currently the most prevalent genotype. Vaccination against these two pathogens helps mitigate their impact on pig health and performance. The use of ready-to-mix or ready-to-use (RTU) vaccines targeting PCV-2a or PCV-2a/b and M. hyo is a common practice. This study aimed to evaluate the efficacy of a novel RTU vaccine containing PCV-2d and M. hyo antigens under experimental conditions. Several challenge trials were conducted using PCV-2a, PCV-2b, PCV-2d, and M. hyo to assess the level of protection conferred against different PCV-2 genotypes and M. hyo, as well as to determine the duration of protection. This study demonstrated that the bivalent PCV-2/M. hyo vaccine induces both early and long-lasting protection against infections caused by M. hyo and PCV-2. In addition, cross-protection against the three major PCV-2 genotypes was confirmed.

Keywords: enzootic pneumonia; PCV-2 disease; vaccination (search for similar items in EconPapers)
Date: 2025
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://vetmed.agriculturejournals.cz/doi/10.17221/6/2025-VETMED.html (text/html)
http://vetmed.agriculturejournals.cz/doi/10.17221/6/2025-VETMED.pdf (application/pdf)
free of charge

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:caa:jnlvet:v:70:y:2025:i:6:id:6-2025-vetmed

DOI: 10.17221/6/2025-VETMED

Access Statistics for this article

Veterinární medicína is currently edited by Bc. Adéla Zvěřinová MSc

More articles in Veterinární medicína from Czech Academy of Agricultural Sciences
Bibliographic data for series maintained by Ivo Andrle ().